ALX Oncology raises $105 million in Series C financing for CD47 trials
By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Chancellor Rishi Sunak pledges £100bn to transform UK’s infrastructure
Chancellor Rishi Sunak pledges £100bn to transform UK’s infrastructure
By Akshay Kedari

As per the statement of chancellor Rishi Sunak, Britain’s first nationwide infrastructure plan would provide a “once in a lifetime investment” of approximately £100 billion to drive the nation’s recovery from the COVID-1...

Telus Communications selects Nokia to deliver 5G services in Canada
Telus Communications selects Nokia to deliver 5G services in Canada
By Akshay Kedari

According to reliable sources, Nokia Corporation has reportedly been selected by Canada-based Telus Communications Inc. to provide 5G services in Canada. The Finnish multinational technology giant will reportedly support the Canadian mobile service o...

TBI, Oracle to jointly launch cloud-based vaccine management system
TBI, Oracle to jointly launch cloud-based vaccine management system
By Akshay Kedari

Tony Blair Institute (TBI) and Oracle have recently introduced cloud technology to Africa for effective management of public health programs in the region. As per credible sources, initially, Ghana, Sierra Leone and Rwanda will use the new Oracl...

Minerva Bunkering unveils ADP for better clarity in bunker deliveries
Minerva Bunkering unveils ADP for better clarity in bunker deliveries
By Akshay Kedari

Swiss supplier of marine fuels Minerva Bunkering has reportedly introduced an innovative solution called Advanced Delivery Platform (ADP) in a bid to increase efficiency and transparency during bunkering operations. According to reliable sources, Min...

TestGorilla secures $1.2M in CapitalT-led pre-Series A funding round
TestGorilla secures $1.2M in CapitalT-led pre-Series A funding round
By Akshay Kedari

In a pre-Series A funding initiative led by a consortium of international angel investors and CapitalT, pre-employment testing software player, TestGorilla, has reportedly secured an amount of USD 1.2 million. This announcement comes amid TestGorilla...